NASDAQ · RCEL
Avita Medical Inc.
$16.71+$0.21 (+1.27%)
Avita Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
Loading market information…
NASDAQ · VANI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vivani Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vivani Medical, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vivani Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 31, 2025 |
| -$0.11-10.0% vs estimate |
| $398.00K |
| Q3 2024 | Nov 13, 2024 | -$0.110.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $4.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$16.71+$0.21 (+1.27%)
Avita Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
$4.76-$0.03 (-0.52%)
Edap Tms S.a.’s quoted price sits in the upper half of its reported 52-week range, 5.84% below the high.
$4.23+$0.07 (+1.68%)
Oramed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.67% below the high.
$3.65$0.00 (0.0%)
Quipt Home Medical Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$1.17$0.00 (0.0%)
Cardiol Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$19.09$0.00 (0.0%)
Fonar Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.34% below the high.
$1.12$0.00 (0.0%)
Microbot Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.84% below the high.
$0.74-$0.04 (-5.23%)
Hyperfine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.67% below the high.
